IBCSG 47-14 BRAVO

  • A phase III, randomized, open label, multicenter, controlled trial of
    niraparib versus physician’s choice in previously-treated, HER2
    negative, germline BRCA mutation-positive breast cancer
    patients.

    • Study Chair
      Dr. Marco Colleoni, EIO Milano, Italy, Nick Turner

      Statistician
      Jan Bogaerts

      Trial Coordinator
      Poonam Jani 

      IBCSG Data Management Center/Frontier Science Foundation
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      Date of Activation
      April 1, 2014

      Targeted Accrual
      306

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login